Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Tango Therapeutics, Inc.
Pliant Therapeutics, Inc.
Cogent Biosciences, Inc.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Tango Therapeutics, Inc.
Astellas Pharma Inc
InnoPharmax Inc.
Novartis
Travera Inc
Virogin Biotech Ltd.
J-Pharma Co., Ltd.
Taiho Oncology, Inc.
Hutchmed
Merck Sharp & Dohme LLC
Jazz Pharmaceuticals
Rigel Pharmaceuticals
Arbele Limited
Alentis Therapeutics AG
Taiho Oncology, Inc.
Hoffmann-La Roche
Imugene Limited
AstraZeneca
Eisai Inc.
Elevar Therapeutics
Seagen Inc.
Servier
Arvinas Inc.
Myeloid Therapeutics
Servier
New Phase Ltd.
Amgen
xCures
DualityBio Inc.
Bold Therapeutics, Inc.
SOFIE
Genfit
Seagen Inc.
TransThera Sciences (Nanjing), Inc.
Apollo Therapeutics Ltd
Taiho Oncology, Inc.
iOMEDICO AG
Alaunos Therapeutics
Massive Bio, Inc.
TriSalus Life Sciences, Inc.
Incyte Corporation
Actym Therapeutics, Inc.